Moderna (MRNA) posts a wider loss and cuts guidance as Covid vaccine sales drop. Its adjusted EPS came in at -$9.53 versus an estimated -$2.01 and revenue came in at $1.83B versus an estimated $1.33B. Moderna CFO Jamey Mock joins Oliver Renick to give an overview of the company. He talks about how MRNA sees at least $6B of Covid-19 vaccine sales in 2023. MRNA expects 50M doses in the U.S. this fall, which was previously estimated at 50M-100M doses. Mock then goes over what’s in the pipeline for MRNA. Tune in to find out more about the stock market today.